2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions

View by Date

Thursday, June 23, 2016

12:00pm-1:30pm: Early retirement and loss of income among X linked dystonia parkinsonism (XDP / DYT3) patients in Capiz, Roxas City Philippines

P.J.B. Acuna, C.L. Go (Boston, MA, USA)

Dystonia · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: ECG-based cardiopulmonary coupling for sleep stability assessment in patients with amyotrophic lateral sclerosis

S. Mariani, P. Congiu, G. Milioli, G. Gioi, G. Borghero, F. Marrosu, R.J. Thomas, A.L. Goldberger, M. Puligheddu (Boston, MA, USA)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: EEG Spectral power changes prior to non-epileptic seizures: A pilot study

A.M. Meppelink, I. Parees, M. Beudel, S. Little, M. Edwards (Groningen, Netherlands)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Effect of botulinum toxin on the non-motor symptoms of dystonia

E. Shakweh, R. Pearce, N. Pavese (London, United Kingdom)

Dystonia · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism

M.U. Kulmanova (Tashkent, Uzbekistan)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia

W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, M. Sanchez, W. Shanahan (New York, NY, USA)

Other · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Effect of outside influences on the therapeutic benefits of botulinum toxin injections

D.C. Taylor, P.A. LeWItt, P. Kaminski (Royal Oak, MI, USA)

Clinical trials and therapy in movement disorders · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Effect of over(exaggerated) articulation technique in voice and speech of individuals with Parkinson’s disease with deep brain stimulation

G.L.A. Diaféria, F.A.M. Bento, M. Padovani, E.T. Fonoff, M.S. Behlau (São Paulo, Brazil)

Parkinson's disease: Clinical trials, pharmacology and treatment · Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm: Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study

P.A. LeWitt, M.I. Freed, M. Leinonen, A. Sedkov, H. Murck (West Bloomfield, MI, USA)

Parkinson's Disease: Clinical Trials II and Non-PD Clinical Trials

12:00pm-1:30pm: Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study

C. Stuijt, T.V. Laar (Groningen, Netherlands)

Pharmacology